Report of Foreign Issuer (6-k)
February 20 2018 - 1:06PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
20
February 2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc (the '
Company
')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
12,482
(Deferred)
|
|
|
|
£0.0000
|
8,614
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
21,096
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1563
|
5,868 (Deferred)
|
|
|
|
£13.1563
|
4,050 (Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
9,918
|
|
Aggregated
volume Price
|
£13.1563
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
9,142
(Deferred)
|
|
|
|
£0.0000
|
6,308
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
15,450
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
|
a)
|
Name
|
Mr R Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1028
|
4,384
(Deferred)
|
|
|
|
£13.1200
|
3,026
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
7,410
|
|
|
Aggregated
volume Price
|
£13.1114
|
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
17,435
(Deferred)
|
|
|
|
£0.0000
|
12,030
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
29,465
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
|
a)
|
Name
|
Mr S Dingemans
|
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1236
|
8,360
(Deferred)
|
|
|
|
£13.1230
|
5,768
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
14,128
|
|
|
Aggregated
volume Price
|
£13.1233
|
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
6,402
(Deferred)
|
|
|
|
£0.0000
|
4,418
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
10,820
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
|
a)
|
Name
|
Mr N Hirons
|
|
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1068
|
3,070
(Deferred)
|
|
|
|
£13.1118
|
2,120
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
5,190
|
|
|
Aggregated
volume Price
|
£13.1093
|
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
10,258
(Deferred)
|
|
|
|
£0.0000
|
7,078
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
17,336
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
|
a)
|
Name
|
Mr D Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1800
|
4,822
(Deferred)
|
|
|
|
£13.1800
|
3,328
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
8,150
|
|
|
Aggregated
volume Price
|
£13.1800
|
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
13,805
(Deferred)
|
|
|
|
£0.0000
|
9,525
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
23,330
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1180
|
6,489
(Deferred)
|
|
|
|
£13.1180
|
4,478
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
10,967
|
|
Aggregated
volume Price
|
£13.1180
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr P Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
4,689
(Deferred)
|
|
|
|
£0.0000
|
3,235
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
7,924
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-19
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr P Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 19 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1240
|
2,204
(Deferred)
|
|
|
|
£13.1240
|
1,521
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
3,725
|
|
Aggregated
volume Price
|
£13.1240
|
|
e)
|
Date
of the transaction
|
2018-02-19
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr P Vallance
|
|
b)
|
Position/status
|
Outgoing President, R&D
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
20,322
(Deferred)
|
|
|
|
£0.0000
|
14,022
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
34,344
|
|
Aggregated
volume Price
|
£0.0000
|
|
e)
|
Date
of the transaction
|
2018-02-19
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr P Vallance
|
|
b)
|
Position/status
|
Outgoing President, R&D
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares following the exercise of options on 19
February 2018 under the Company's Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1760
|
20,322
(Deferred)
|
|
|
|
£13.1760
|
14,022
(Matching)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
34,344
|
|
Aggregated
volume Price
|
£13.1180
|
|
e)
|
Date
of the transaction
|
2018-02-19
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
20, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
